مباشر
Merck KGaAMerck KGaA taps into Remepy’s Hybrid Drug platform - The Pharma LetterGE HealthCareGE HealthCare’s stock plunges 13% as supply chain costs bite - Medical Device NetworkBioPharma DiveMerck still sees ‘compelling’ outlook for Terns leukemia drugMerck & Co.Merck & Co lifts outlook as Keytruda growth offsets acquisition hit - The Pharma LetterCellProteostasis sustains T cell differentiation potential and tumor-infiltrating lymphocyte functionCellDifferential inhibition of <em>Morbillivirus</em> and <em>Henipavirus</em> polymerases by ERDRP-0519 and structure-guided inhibitor optimizationBioPharma DiveUniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapyMerck & Co.Merck's growth products Winrevair, Ohtuvayre trending in opposite directions - Fierce PharmaEndpoints NewsAvalyn's upsized IPO; Alector ends another study in GSK partnershipEndpoints NewsAnalysts focus on three programs in big year for Bristol MyersBioPharma DiveLilly posts another ‘blowout quarter’ as focus turns to Foundayo launchEndpoints NewsXTL Bio to acquire psychedelic biotech; WuXi AppTec’s Q1 revenue rise
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.